Associations of MTX-PG concentrations with EULAR good response, DAS28 remission and ΔHAQ-DI
| N | MTX-PG1 (nmol/L) | p Value | MTX-PG2 (nmol/L) | p Value | MTX-PG3 (nmol/L) | p Value | Total MTX-PG (nmol/L) | p Value | |
|---|---|---|---|---|---|---|---|---|---|
| Week 4 | |||||||||
| Remission (+) | 23 | 27.1 | 0.51 | 11.8 | 0.58 | 3.1 | 0.75 | 41.3 | 0.48 |
| Remission (−) | 56 | 28.9 | 12.9 | 3.4 | 44.8 | ||||
| Good response (+) | 18 | 27.9 | 0.85 | 14.6 | 0.19 | 5.1 | 0.46 | 46.6 | 0.50 |
| Good response (−) | 61 | 28.5 | 11.9 | 4.8 | 42.9 | ||||
| ΔHAQ, β (SE) | 79 | −0.002 (0.006) | 0.68 | 0.004 (0.009) | 0.49 | 0.003 (0.014) | 0.7 | −0.002 (0.003) | 0.95 |
| Week 8 | |||||||||
| Remission (+) | 33 | 40.7 | 0.25 | 22.8 | 8.3 | 10.4 | 0.40 | 71.2 | 0.85 |
| Remission (−) | 45 | 36.9 | 23.3 | 9.1 | 72.3 | ||||
| Good response (+) | 33 | 38.8 | 0.97 | 22.0 | 0.39 | 10.4 | 0.52 | 71.2 | 0.85 |
| Good response (−) | 45 | 39.0 | 23.8 | 9.4 | 72.3 | ||||
| ΔHAQ, β (SE) | 78 | 0.001 (0.005) | 0.11 | 0.002 (0.008) | 0.24 | −0.011 (0.011) | 0.29 | −0.000 (0.003) | 0.93 |
| Week 12 | |||||||||
| Remission (+) | 46 | 50.4 | 0.02* | 30.5 | 0.14 | 16.9 | 0.87 | 97.3 | 0.09 |
| Remission (−) | 30 | 40.6 | 26.7 | 16.6 | 84.3 | ||||
| Good response (+) | 39 | 51.1 | 0.007* | 32.2 | 0.004* | 18.8 | 0.08 | 101.1 | 0.001* |
| Good response (−) | 37 | 40.1 | 24.9 | 14.6 | 75.9 | ||||
| ΔHAQ, β (SE) | 76 | −0.009 (0.005) | 0.08 | −0.005 (0.008) | 0.05 | −0.011 (0.008) | 0.23 | −0.004 (0.003) | 0.11 |
| Week 24 | |||||||||
| Remission (+) | 35 | 48.7 | 0.03* | 34.6 | 0.02* | 24.7 | 0.09 | 109.1 | 0.001* |
| Remission (−) | 14 | 34.9 | 23.2 | 17.4 | 66.4 | ||||
| Good response (+) | 37 | 35.2 | 0.05* | 33.9 | 0.04* | 23.4 | 0.50 | 102.1 | 0.11 |
| Good response (−) | 12 | 27.9 | 23.4 | 20.3 | 80.8 | ||||
| ΔHAQ, β (SE) | 49 | −0.015 (0.006) | 0.02* | −0.018 (0.008) | 0.04* | −0.019 (0.010) | 0.07 | −0.008 (0.003) | 0.02* |
| Week 36 | |||||||||
| Remission (+) | 37 | 46.4 | 0.18 | 30.2 | 0.32 | 21.7 | 0.48 | 98.8 | 0.22 |
| Remission (−) | 5 | 33.7 | 24.3 | 17.6 | 75.6 | ||||
| Good response (+) | 33 | 46.1 | 0.46 | 30.4 | 0.41 | 22.6 | 0.16 | 99.3 | 0.25 |
| Good response (−) | 9 | 40.5 | 26.5 | 16.2 | 83.9 | ||||
| ΔHAQ, β (SE) | 42 | −0.012 (0.009) | 0.19 | −0.020 (0.014) | 0.17 | −0.038 (0.016) | 0.03* | −0.014 (0.006) | 0.03* |
| Week 52 | |||||||||
| Remission (+) | 32 | 39.8 | 0.07 | 27.6 | 0.72 | 16.8 | 0.18 | 84.0 | 0.13 |
| Remission (−) | 4 | 55.9 | 30.1 | 25.0 | 111.0 | ||||
| Good response (+) | 28 | 39.9 | 0.24 | 27.0 | 0.46 | 17.7 | 0.08 | 84.2 | 0.31 |
| Good response (−) | 8 | 47.8 | 30.8 | 18.0 | 96.7 | ||||
| ΔHAQ, β (SE) | 36 | −0.026 (0.014) | 0.07 | −0.016 (0.017) | 0.33 | −0.006 (0.020) | 0.76 | −0.005 (0.007) | 0.43 |
| Week 76 | |||||||||
| Remission (+) | 31 | 45.4 | 0.99 | 26.2 | 0.51 | 17.5 | 0.99 | 89.3 | 0.72 |
| Remission (−) | 3 | 45.5 | 30.2 | 17.4 | 93.1 | ||||
| Good response (+) | 28 | 44.5 | 0.51 | 26.1 | 0.51 | 17.8 | 0.68 | 88.6 | 0.55 |
| Good response (−) | 6 | 49.5 | 29.0 | 15.8 | 94.7 | ||||
| ΔHAQ, β (SE) | 34 | −0.008 (0.011) | 0.49 | 0.000 (0.017) | 0.98 | −0.002 (0.016) | 0.90 | −0.002 (0.006) | 0.72 |
*p<0.05.
DAS28, Disease Activity Score for 28 joints; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; MTX-PG, methotrexate polyglutamate.